Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

54.30 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
The 3 Things That Matter for Viking Therapeutics Now
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations. 
Via The Motley Fool
September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
September 30, 2025 Deadline: Contact Levi &amp; Korsinsky to Join Class Action Suit Against NVO
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases. 
Via Benzinga
Topics Lawsuit
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026. 
Via Benzinga
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock
Investors have a tough choice between these two excellent companies. 
Via The Motley Fool
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Value Investment with Undervalued Potential
NOVO-NORDISK (NVO) is a top value stock with strong fundamentals, undervalued metrics, high profitability, and steady growth in diabetes & obesity care markets. 
Via Chartmill
Novo Nordisk Stock: Buy or Sell?
News from a competitor is increasing enthusiasm for Novo Nordisk stock. 
Via The Motley Fool
Is the Market Bullish or Bearish on Novo Nordisk?
 
Via Benzinga
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Shareholders That lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Shareholders That lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
4 of the Most Undervalued Stocks in the Market Right Now
They all offer great value right now. 
Via The Motley Fool
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade
These two underappreciated dividend payers offer above-average yields and relatively rapid payout growth. 
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats. 
Via MarketBeat
Topics Government World Trade
MarketBeat Week in Review – 08/04 - 08/08
Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales 
Via MarketBeat
Topics ETFs Economy World Trade
Why Hims & Hers Stock Sank This Week
The telehealth platform is growing quickly but is in the middle of a legal battle. 
Via The Motley Fool
Topics Lawsuit
Why Novo Nordisk Stock Flew Higher on Friday
It looked good next to a company that has been stealing its thunder lately. 
Via The Motley Fool
Deadline Approaching: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone. 
Via MarketBeat
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk Stock Investors Need to Know This
The company is using litigation to protect sales of its most popular treatments. 
Via The Motley Fool
Novo Nordisk Is Down 70%: Is the Price Too Low To Ignore?
Investors shouldn't expect a V-shaped recovery. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.